Connor Clark & Lunn Investment Management Ltd. Has $44.71 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Connor Clark & Lunn Investment Management Ltd. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 789.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 227,512 shares of the medical research company’s stock after acquiring an additional 201,945 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.13% of IQVIA worth $44,708,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Raymond James Financial Inc. bought a new position in IQVIA in the fourth quarter worth approximately $236,120,000. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA in the third quarter valued at approximately $147,683,000. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on IQV. Barclays dropped their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Morgan Stanley lifted their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

Shares of NYSE IQV opened at $185.47 on Thursday. The stock has a market cap of $32.70 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.72. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a fifty day moving average of $197.14 and a 200-day moving average of $211.59.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.